Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04301323Phase 1Completed

Myopia Control With Novel Eye Drops

Role: lead

NCT04048148Not ApplicableUnknown

Myopia Progression Trial With Novel Myopia Control Design Spectacle Lenses

Role: collaborator

NCT03690414Phase 1Completed

Evaluation of Short Term Use of Experimental Eye Drops BHVI2, 0.02% Atropine and BHVI2 Plus 0.02% Atropine Eye Drops

Role: lead

NCT03699423Phase 1Completed

Effects of Low Concentration Atropine on Pupillary Size and Accommodative Amplitude

Role: lead

All 4 trials loaded